A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria

Bronchitis, Chronic Clinical Trial

Official title:
A Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With That of Cefuroxime Axetil in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis in Adults

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with cefuroxime axetil, another antibiotic, in the treatment of adults with chronic bronchitis experiencing rapid onset of worsening of symptoms caused by bacteria.

Clinical Trial Description

This is a randomized, open-label, parallel group, multicenter study to determine the safety and effectiveness of 500 mg of levofloxacin (once daily for 5 - 7 days) compared with 250 mg of cefuroxime axetil (every 12 hours for 10 days) in adults with chronic bronchitis experiencing rapid onset of severe worsening of symptoms caused by bacteria. The study consists of 3 visits: one visit for screening and enrollment, and 2 visits for assessment of safety and effectiveness (one visit on Days 3 - 5 of the study and one visit [post-therapy] 5 - 7 days after the last dose of the study drug). The total duration of patient participation in the study is approximately 2 weeks. The primary efficacy assessment is the clinical response 5 - 7 days after the last dose of study drug, (categorized as cured, improved, or failed) based upon changes in signs and symptoms. Safety evaluations (incidence of adverse events, physical examination, laboratory tests) are performed throughout the study. The study hypothesis is that treatment with levofloxacin is at least as effective and as well tolerated as treatment with cefuroxime axetil in adult patients with chronic bronchitis experiencing sudden worsening of symptoms caused by bacterial infection. Levofloxacin 500 mg by mouth once daily for 5 - 7 days, or cefuroxime axetil 250 mg by mouth every 12 hours for 10 days ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00269932
Study type	Interventional
Source	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact
Status	Completed
Phase	Phase 3
Start date	August 1993
Completion date	May 1994

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00245453` - Outpatient Registry Trial of Respiratory Tract Infections in Adults	Phase 4
Completed	`NCT00473460` - Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis	Phase 3
Completed	`NCT00649831` - A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis	Phase 3
Completed	`NCT01507415` - Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?	N/A
Active, not recruiting	`NCT00608764` - Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)
Completed	`NCT00538148` - Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD	Phase 4
Completed	`NCT02637219` - Innate Immune Response in COPD	N/A
Completed	`NCT00406705` - The Effect of Breathing Helium-Hyperoxia During Pulmonary Rehabilitation in Patients With COPD	Phase 2
Completed	`NCT00257140` - A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria	Phase 2/Phase 3
Completed	`NCT01719822` - Physical Activity Augmentation Using Pedometers During Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease	N/A
Terminated	`NCT02261350` - Post-hospitalisation Nutritional Support and Gait Speed in COPD	Phase 3
Completed	`NCT01495780` - eRT Remote Health Monitoring	N/A
Completed	`NCT01077102` - Eccentric Exercise Training as Novel Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD)	N/A
Terminated	`NCT00288223` - Telithromycin in Acute Exacerbation of Chronic Bronchitis	Phase 4
Completed	`NCT00644449` - A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis	Phase 3
Completed	`NCT00423137` - Effect of BIBW 2948 BS in COPD	Phase 2
Completed	`NCT02483637` - Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients	N/A
Completed	`NCT00932802` - Greatest International Antiinfective Trial With Avelox	N/A
Completed	`NCT00245427` - Outcomes of Patients Not Responding to Antibiotics in the Community	N/A
Completed	`NCT00035828` - A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD	Phase 2